Please wait while your request is being verified...
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Clene Inc. - Common Stock (NQ:CLNN)

8.050 -0.550 (-6.40%)
Streaming Delayed Price Updated: 3:14 PM EDT, Oct 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Clene Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Landmark Study Shows How Menopause Influences the Symptoms of Multiple Sclerosis
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Presents Positive REPAIR-MS Results at ECTRIMS 2025
Via Investor Brand Network
New Smart Pen Shows 96% Efficacy in Detecting Parkinson’s Disease
Via Investor Brand Network
Clene Inc.’s (NASDAQ: CLNN) Lead Candidate CNM-Au8(R) Shows Promise in Improving Cellular Health in Parkinson’s Disease
Via Investor Brand Network
MissionIRNewsBreaks – Clene Inc. (NASDAQ: CLNN) Advances Toward NDA Submission for ALS Therapy
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Presents Preclinical Data Showing CNM-Au8 Improves Cellular Health in Parkinson’s Disease Model
Via Investor Brand Network
Research Uncovers Possible Way to Repair Myelin in MS Patients
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at H.C. Wainwright Global Investment Conference
Via Investor Brand Network
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Builds Late-Stage Momentum in Neuro Pipeline
Via Investor Brand Network
Pioneering Therapy Could Slow the Effects of Aging
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Reports Q2 2025 Results as Company Prepares for NDA Submission and Extends Runway into 2026
Via Investor Brand Network
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Reports Q2 2025 Results, Targets Year-End NDA Submission for ALS Therapy
Via Investor Brand Network
Clene Posts 70% Revenue Drop in Q2
Via The Motley Fool
InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present Corporate Update at Emerging Growth Conference on Aug. 20
Via Investor Brand Network
Parkinson’s-Gut Bacteria Link Suggests Surprisingly Simple Treatment Option
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) to Present at Canaccord 45th Annual Growth Conference
Via Investor Brand Network
New AI-Based Speech Tool Detects Possibility of Parkinson’s Disease
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Offers Investors a Compelling Entry into the Growing ALS Market with Key FDA Milestones for Lead Drug Candidate
Via Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Builds Momentum to Bring New Hope to Neuro Patients
Via Investor Brand Network
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Individuals Who Develop Multiple Sclerosis Have More Doctor Visits Decades Before Their Diagnosis
Via Investor Brand Network
Preclinical Study Finds a Way to Reverse Symptoms of Parkinson’s in Mice
Via Investor Brand Network
Clene Inc. (NASDAQ: CLNN) to Conduct Neurofilament Biomarker Analysis for CNM-Au8(R) in ALS in Early Q4 2025
Via Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Advances Regulatory Strategy for CNM-Au8 with FDA Meetings Scheduled for ALS and MS Programs
Via Investor Brand Network
Why Public Interest in Mitochondrial Function Testing is Growing
Via Investor Brand Network
Q2 Virtual Investor Summit: Presentations Available Now
Via ACCESS Newswire
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream
Via Stocktwits
Study Finds Kids with MS Biologically Age Faster Than Those Without It
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.